Use of a biomimetic hydrogel depot technology for sustained delivery of GLP-1 receptor agonists reduces burden of diabetes management.
GLP-1 RA
diabetes
drug delivery
supramolecular hydrogel
Journal
Cell reports. Medicine
ISSN: 2666-3791
Titre abrégé: Cell Rep Med
Pays: United States
ID NLM: 101766894
Informations de publication
Date de publication:
21 Nov 2023
21 Nov 2023
Historique:
received:
16
03
2023
revised:
02
08
2023
accepted:
23
10
2023
medline:
24
11
2023
pubmed:
23
11
2023
entrez:
22
11
2023
Statut:
ppublish
Résumé
Glucagon-like peptide-1 (GLP-1) is an incretin hormone and neurotransmitter secreted from intestinal L cells in response to nutrients to stimulate insulin and block glucagon secretion in a glucose-dependent manner. Long-acting GLP-1 receptor agonists (GLP-1 RAs) have become central to treating type 2 diabetes (T2D); however, these therapies are burdensome, as they must be taken daily or weekly. Technological innovations that enable less frequent administrations would reduce patient burden and increase patient compliance. Herein, we leverage an injectable hydrogel depot technology to develop a GLP-1 RA drug product capable of months-long GLP-1 RA delivery. Using a rat model of T2D, we confirm that one injection of hydrogel-based therapy sustains exposure of GLP-1 RA over 42 days, corresponding to a once-every-4-months therapy in humans. Hydrogel therapy maintains management of blood glucose and weight comparable to daily injections of a leading GLP-1 RA drug. This long-acting GLP-1 RA treatment is a promising therapy for more effective T2D management.
Identifiants
pubmed: 37992687
pii: S2666-3791(23)00486-X
doi: 10.1016/j.xcrm.2023.101292
pmc: PMC10694761
pii:
doi:
Substances chimiques
Hypoglycemic Agents
0
Glucagon-Like Peptide-1 Receptor
0
Hydrogels
0
Glucagon-Like Peptide 1
89750-14-1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
101292Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests A.I.D., C.L.M., L.T.N., and E.A.A. are listed on a patent describing the technology reported in this work. L.H., D.B.S., and H.B.A. declare the following potential competing interest with respect to the research, authorship, and/or publication of this article: the authors are full-time employees and shareholders of Novo Nordisk A/S.
Références
J Vis Exp. 2021 Feb 7;(168):
pubmed: 33616104
Cell Metab. 2018 Jul 03;28(1):23-32.e3
pubmed: 29861388
Biomater Sci. 2023 Mar 14;11(6):2065-2079
pubmed: 36723072
Front Endocrinol (Lausanne). 2019 Apr 12;10:155
pubmed: 31031702
J Lipid Res. 1975 May;16(3):165-79
pubmed: 236351
N Engl J Med. ;376(9):890
pubmed: 28252261
Curr Opin Biotechnol. 2011 Dec;22(6):868-76
pubmed: 21862310
Patient Prefer Adherence. 2016 Jul 22;10:1299-307
pubmed: 27524885
Eur J Pharmacol. 2002 Sep 13;451(2):217-25
pubmed: 12231394
Lancet. 2019 Jul 13;394(10193):121-130
pubmed: 31189511
Macromol Biosci. 2021 Feb;21(2):e2000295
pubmed: 33164332
Exp Biol Med (Maywood). 2012 May;237(5):481-90
pubmed: 22619373
Mol Metab. 2021 Apr;46:101102
pubmed: 33068776
J Clin Pathol. 2008 Apr;61(4):401-9
pubmed: 18375745
Br J Pharmacol. 2003 Sep;140(1):123-32
pubmed: 12967942
Clin Diabetes. 2022 Jan;40(1):10-38
pubmed: 35221470
Diabetes Res Clin Pract. 2020 Apr;162:108072
pubmed: 32061820
N Engl J Med. 2015 Jul 2;373(1):11-22
pubmed: 26132939
Soft Matter. 2020 Nov 18;16(44):10122-10131
pubmed: 32780784
Biomaterials. 2014 Dec;35(37):9897-9903
pubmed: 25239043
J Control Release. 2014 Sep 28;190:240-53
pubmed: 24929039
Nat Rev Dis Primers. 2015 Jul 23;1:15019
pubmed: 27189025
J Clin Endocrinol Metab. 2014 Jun;99(6):1983-92
pubmed: 24712577
Clin Interv Aging. 2009;4:259-67
pubmed: 19554097
ACS Biomater Sci Eng. 2021 Sep 13;7(9):4221-4229
pubmed: 34510910
J Diabetes. 2020 Oct;12(10):742-753
pubmed: 32567125
Bioeng Transl Med. 2019 Oct 22;5(1):e10147
pubmed: 31989036
Eur J Pharm Sci. 2017 Jun 15;104:31-41
pubmed: 28323117
N Engl J Med. 2021 May 6;384(18):1719-1730
pubmed: 33951361
Clin Pharmacokinet. 2018 Dec;57(12):1529-1538
pubmed: 29915923
Nat Commun. 2015 Feb 19;6:6295
pubmed: 25695516
J Basic Clin Pharm. 2016 Mar;7(2):27-31
pubmed: 27057123
Diabetes Ther. 2021 May;12(5):1475-1489
pubmed: 33837922
JCI Insight. 2020 Mar 26;5(6):
pubmed: 32213703
Curr Protoc Pharmacol. 2008 Mar;Chapter 5:Unit 5.47
pubmed: 22294227
Curr Diab Rep. 2017 Sep 23;17(11):111
pubmed: 28942594
Lancet. 2009 Nov 7;374(9701):1606-16
pubmed: 19853906
Macromol Biosci. 2019 Jan;19(1):e1800275
pubmed: 30369048
N Engl J Med. 2016 Jul 28;375(4):311-22
pubmed: 27295427
Diabetes Care. 2019 Sep;42(9):1661-1668
pubmed: 30940641
J Med Chem. 2015 Feb 12;58(3):1020-37
pubmed: 25349901
Gastroenterology. 2007 May;132(6):2131-57
pubmed: 17498508
Nat Biomed Eng. 2019 Aug;3(8):611-620
pubmed: 31391596
Oman Med J. 2012 Jul;27(4):269-73
pubmed: 23071876
Int J Clin Pract. 2021 Sep;75(9):e14060
pubmed: 33527605
Nat Commun. 2021 Feb 2;12(1):746
pubmed: 33531475
Patient Prefer Adherence. 2018 May 07;12:707-719
pubmed: 29765207
J Med Chem. 2015 Sep 24;58(18):7370-80
pubmed: 26308095
N Engl J Med. 2021 Mar 18;384(11):989-1002
pubmed: 33567185
ACS Cent Sci. 2020 Oct 28;6(10):1800-1812
pubmed: 33145416
ACS Biomater Sci Eng. 2021 May 10;7(5):1889-1899
pubmed: 33404236
Sci Adv. 2022 Apr 8;8(14):eabn8264
pubmed: 35394838
P T. 2010 Sep;35(9):498-529
pubmed: 20975808
Chem Rev. 2021 Sep 22;121(18):11385-11457
pubmed: 33938724
N Engl J Med. 2020 Nov 26;383(22):2107-2116
pubmed: 32960514
Diabetes Obes Metab. 2017 Sep;19(9):1242-1251
pubmed: 28266779
Horm Res Paediatr. 2023;96(6):599-608
pubmed: 34852347
Adv Healthc Mater. 2019 Mar;8(5):e1801147
pubmed: 30714355
J Pharm Sci. 2013 Oct;102(10):3844-51
pubmed: 23897494
Diabetes. 1998 Feb;47(2):224-9
pubmed: 9519717